Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medical Developments International's share price is €0.258.
Medical Developments International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.21. Hence, Medical Developments International's PS Ratio for today is 1.26.
Medical Developments International (FRA:M5D) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medical Developments International PS Ratio Related Terms
Medical Developments International PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medical Developments International's PS Ratio falls into.
Medical Developments International PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medical Developments International's Share Price of today is €0.258.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Developments International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medical Developments International (FRA:M5D) has a PS Ratio of 1.26 as of Aug. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medical Developments International and its competitors. This is 90% below median its historical median of 13.21. Over the past decade, Medical Developments International's PS Ratio has ranged from 1.05 to 34.24. According to the industry distribution chart, Medical Developments International ranks #314 out of 952 companies in the Drug Manufacturers industry, placing it in the top 33%.
Is Medical Developments International's PS Ratio too high?
Medical Developments International's current PS Ratio of 1.26 is 90% below median its 10-year median of 13.21. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 34.24. The Drug Manufacturers industry median PS Ratio is 2.37. Medical Developments International's value of 1.26 is 46.7% below this industry median. Based on the distribution chart, Medical Developments International ranks #314 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medical Developments International has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #314 out of 952 companies for PS Ratio. This puts Medical Developments International in the upper half of its industry. The industry median PS Ratio is 2.37. Medical Developments International's value of 1.26 is 46.7% below this benchmark. Historically, Medical Developments International's own PS Ratio has ranged from 1.05 to 34.24 over the past decade. While the company's 10-year median is 13.21 vs. the industry median of 2.37, Medical Developments International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.37, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current PS Ratio of 1.26 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current PS Ratio is 1.26, which is 90% below median its own 10-year median of 13.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Medical Developments International (FRA:M5D) has a current PS Ratio of 1.26. The stock's GF Value™ is €0.33, compared to a current price of €0.26 — trading 21.8% below its estimated fair value. The current PS Ratio is 1.26, which is 90% below median its 10-year median of 13.21 and 46.7% below the Drug Manufacturers industry median of 2.37. Medical Developments International's overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current PS Ratio is 1.26 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (FRA:M5D) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of €0.26 is trading 21.8% below its estimated GF Value™ of €0.33.
Key valuation signals for FRA:M5D:
PS Ratio: 1.26 (90% below median its 10-year median of 13.21)
GF Value™: €0.33 vs. price of €0.26 (21.8% below fair value)
Industry Position: 46.7% below the Drug Manufacturers median (#314 of 952)
No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
46GF Score
Get the complete analysis for FRA:M5D
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M5D has been successfully added to your 
